{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:57:20Z","timestamp":1792706240481,"version":"4.5.0"},"reference-count":187,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"am","delay-in-days":373,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K08 CA255932"],"award-info":[{"award-number":["K08 CA255932"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001021","name":"Damon Runyon Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005968","name":"Leukemia Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cancer"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.trecan.2024.01.003","type":"journal-article","created":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T04:17:34Z","timestamp":1707797854000},"page":"312-331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology"],"prefix":"10.1016","volume":"10","author":[{"given":"Gabriele J.","family":"Kembuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna Y.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela V.","family":"Maus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Jan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trecan.2024.01.003_bb0005","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2024.01.003_bb0010","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2020-139605","article-title":"CD58 aberrations limit durable responses to CD19 CAR in large B cell lymphoma patients treated with axicabtagene ciloleucel but can be overcome through novel CAR engineering","volume":"136","author":"Majzner","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2024.01.003_bb0015","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1016\/j.ymthe.2020.09.015","article-title":"CAR T cell therapy for solid tumors: bright future or dark reality?","volume":"28","author":"Wagner","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.trecan.2024.01.003_bb0020","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.trecan.2024.01.003_bb0025","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41573-021-00189-2","article-title":"Navigating CAR-T cells through the solid-tumour microenvironment","volume":"20","author":"Hou","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.trecan.2024.01.003_bb0030","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/s41591-023-02276-w","article-title":"Tumor inflammation-associated neurotoxicity","volume":"29","author":"Mahdi","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2024.01.003_bb0035","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR T cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.trecan.2024.01.003_bb0040","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","article-title":"HER2-targeted therapies \u2013 a role beyond breast cancer","volume":"17","author":"Oh","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.trecan.2024.01.003_bb0045","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1158\/1078-0432.CCR-18-2275","article-title":"Advances in HER2-targeted therapy: novel agents and opportunities beyond breast and gastric cancer","volume":"25","author":"Meric-Bernstam","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2024.01.003_bb0050","first-page":"953","article-title":"Expression of the HER-2\/neu proto-oncogene in normal human adult and fetal tissues","volume":"5","author":"Press","year":"1990","journal-title":"Oncogene"},{"key":"10.1016\/j.trecan.2024.01.003_bb0055","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/1878-0261.12102","article-title":"MEK inhibitors induce Akt activation and drug resistance by suppressing negative feedback ERK-mediated HER2 phosphorylation at Thr701","volume":"11","author":"Chen","year":"2017","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.trecan.2024.01.003_bb0060","doi-asserted-by":"crossref","first-page":"105383","DOI":"10.18632\/oncotarget.22194","article-title":"Mek activity is required for ErbB2 expression in breast cancer cells detached from the extracellular matrix","volume":"8","author":"Khan","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.trecan.2024.01.003_bb0065","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/j.1460-2075.1996.tb00356.x","article-title":"ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer","volume":"15","author":"Karunagaran","year":"1996","journal-title":"EMBO J."},{"key":"10.1016\/j.trecan.2024.01.003_bb0070","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1002\/j.1460-2075.1996.tb00603.x","article-title":"Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions","volume":"15","author":"Pinkas-Kramarski","year":"1996","journal-title":"EMBO J."},{"key":"10.1016\/j.trecan.2024.01.003_bb0075","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1128\/MCB.15.3.1182","article-title":"Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling","volume":"15","author":"Graus-Porta","year":"1995","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.trecan.2024.01.003_bb0080","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1093\/emboj\/17.12.3385","article-title":"Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers","volume":"17","author":"Lenferink","year":"1998","journal-title":"EMBO J."},{"key":"10.1016\/j.trecan.2024.01.003_bb0085","doi-asserted-by":"crossref","first-page":"5276","DOI":"10.1128\/MCB.16.10.5276","article-title":"A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor\/neuregulin and epidermal growth factor","volume":"16","author":"Tzahar","year":"1996","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.trecan.2024.01.003_bb0090","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1023\/A:1006491619920","article-title":"Ras activation in human breast cancer","volume":"62","author":"von Lintig","year":"2000","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.trecan.2024.01.003_bb0095","first-page":"003","article-title":"Regulation of apoptosis by HER2 in breast cancer","volume":"2013","author":"Carpenter","year":"2013","journal-title":"J. Carcinog. Mutagen."},{"key":"10.1016\/j.trecan.2024.01.003_bb0100","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.trecan.2024.01.003_bb0105","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1007\/s13238-017-0440-4","article-title":"Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers","volume":"9","author":"Feng","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.trecan.2024.01.003_bb0110","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jamaoncol.2017.0184","article-title":"HER2-specific chimeric antigen receptor-modified virus-specific T Cells for progressive glioblastoma: a phase 1 dose-escalation trial","volume":"3","author":"Ahmed","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.trecan.2024.01.003_bb0115","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2024.01.003_bb0120","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1038\/s41591-021-01404-8","article-title":"Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis","volume":"27","author":"Vitanza","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2024.01.003_bb0125","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1038\/s41467-020-17175-8","article-title":"Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma","volume":"11","author":"Hegde","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2024.01.003_bb0130","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.trecan.2024.01.003_bb0135","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s43018-021-00195-8","article-title":"Overcoming therapy resistance in EGFR-mutant lung cancer","volume":"2","author":"Passaro","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.trecan.2024.01.003_bb0140","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.3389\/fonc.2020.01249","article-title":"The latest battles between EGFR monoclonal antibodies and resistant tumor cells","volume":"10","author":"Cai","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.trecan.2024.01.003_bb0145","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/1878-0261.12155","article-title":"Emerging functions of the EGFR in cancer","volume":"12","author":"Sigismund","year":"2018","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.trecan.2024.01.003_bb0150","doi-asserted-by":"crossref","first-page":"7999","DOI":"10.1038\/ncomms8999","article-title":"Quantitative analysis reveals how EGFR activation and downregulation are coupled in normal but not in cancer cells","volume":"6","author":"Capuani","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2024.01.003_bb0155","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2024.01.003_bb0160","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jcyt.2020.04.088","article-title":"Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: a phase I clinical trial","volume":"22","author":"Liu","year":"2020","journal-title":"Cytotherapy"},{"key":"10.1016\/j.trecan.2024.01.003_bb0165","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13045-016-0378-7","article-title":"Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma","volume":"10","author":"Feng","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.trecan.2024.01.003_bb0170","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s11427-016-5023-8","article-title":"Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed\/refractory non-small cell lung cancer","volume":"59","author":"Feng","year":"2016","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.trecan.2024.01.003_bb0175","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2024.01.003_bb0180","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41568-022-00497-8","article-title":"Oncofetal reprogramming in tumour development and progression","volume":"22","author":"Sharma","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.trecan.2024.01.003_bb0185","first-page":"5914","article-title":"Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients","volume":"44","author":"Schulz","year":"1984","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2024.01.003_bb0190","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/ajcp\/96.2.248","article-title":"Cell-Surface ganglioside GD2 in the immunohistochemical detection and differential diagnosis of neuroblastoma","volume":"96","author":"Sariola","year":"1991","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.trecan.2024.01.003_bb0195","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1182\/blood.V75.7.1564.1564","article-title":"Shed tumor gangliosides and progression of human neuroblastoma","volume":"75","author":"Valentino","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2024.01.003_bb0200","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1073\/pnas.91.5.1974","article-title":"Ceramide structure predicts tumor ganglioside immunosuppressive activity","volume":"91","author":"Ladisch","year":"1994","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.trecan.2024.01.003_bb0205","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41591-021-01625-x","article-title":"Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication","volume":"28","author":"Theruvath","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2024.01.003_bb0210","first-page":"1255","article-title":"Enhancement of malignant properties of human glioma cells by ganglioside GD3\/GD2","volume":"52","author":"Iwasawa","year":"2018","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.trecan.2024.01.003_bb0215","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1186\/s13046-022-02523-x","article-title":"B3GALT4 remodels the tumor microenvironment through GD2-mediated lipid raft formation and the c-Met\/AKT\/mTOR\/IRF-1 axis in neuroblastoma","volume":"41","author":"Sha","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2024.01.003_bb0220","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.3892\/ijo.2015.3070","article-title":"GD2 ganglioside specific antibody treatment downregulates PI3K\/Akt\/mTOR signaling network in human neuroblastoma cell lines","volume":"47","author":"Durbas","year":"2015","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.trecan.2024.01.003_bb0225","doi-asserted-by":"crossref","first-page":"29828","DOI":"10.1074\/jbc.M414041200","article-title":"Mechanisms for the apoptosis of small cell lung cancer cells induced by anti-GD2 monoclonal antibodies: roles of anoikis","volume":"280","author":"Aixinjueluo","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.trecan.2024.01.003_bb0230","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1517\/14728222.2014.986459","article-title":"Disialoganglioside GD2 as a therapeutic target for human diseases","volume":"19","author":"Suzuki","year":"2015","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.trecan.2024.01.003_bb0235","first-page":"4244","article-title":"Ganglioside G(D2) in small cell lung cancer cell lines: enhancement of cell proliferation and mediation of apoptosis","volume":"61","author":"Yoshida","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2024.01.003_bb0240","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","article-title":"Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma","volume":"363","author":"Yu","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2024.01.003_bb0245","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S1470-2045(18)30578-3","article-title":"Interleukin 2 with anti-GD2 antibody ch14.18\/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1\/SIOPEN): a multicentre, randomised, phase 3 trial","volume":"19","author":"Ladenstein","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2024.01.003_bb0250","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1200\/JCO.2011.41.3807","article-title":"Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission","volume":"30","author":"Cheung","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2024.01.003_bb0255","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.3389\/fimmu.2018.02380","article-title":"CAR T cell therapy for neuroblastoma","volume":"9","author":"Richards","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trecan.2024.01.003_bb0260","doi-asserted-by":"crossref","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","article-title":"Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma","volume":"118","author":"Louis","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2024.01.003_bb0265","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd6169","article-title":"Antitumor activity without on-target off-tumor toxicity of GD2\u2013chimeric antigen receptor T cells in patients with neuroblastoma","volume":"12","author":"Straathof","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.trecan.2024.01.003_bb0270","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nm.1882","article-title":"Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma","volume":"14","author":"Pule","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2024.01.003_bb0275","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1007\/s00432-021-03839-5","article-title":"GD2-specific chimeric antigen receptor-modified T cells for the treatment of refractory and\/or recurrent neuroblastoma in pediatric patients","volume":"148","author":"Yu","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.trecan.2024.01.003_bb0280","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41591-023-02363-y","article-title":"Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results","volume":"29","author":"Heczey","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2024.01.003_bb0285","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/s41591-020-1074-2","article-title":"Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis","volume":"26","author":"Heczey","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2024.01.003_bb0290","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","article-title":"GD2-CART01 for relapsed or refractory high-risk neuroblastoma","volume":"388","author":"Bufalo","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2024.01.003_bb0295","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41591-018-0006-x","article-title":"Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas","volume":"24","author":"Mount","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2024.01.003_bb0300","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2024.01.003_bb0305","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.molonc.2011.02.001","article-title":"The biology of cancer testis antigens: putative function, regulation and therapeutic potential","volume":"5","author":"Fratta","year":"2011","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.trecan.2024.01.003_bb0310","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/BF03401786","article-title":"Molecular expression analysis of restrictive receptor for interleukin 13, a brain tumor-associated cancer\/testis antigen","volume":"6","author":"Debinski","year":"2000","journal-title":"Mol. Med."},{"key":"10.1016\/j.trecan.2024.01.003_bb0315","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev.immunol.21.120601.141142","article-title":"IL-13 effector functions","volume":"21","author":"Wynn","year":"2003","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.trecan.2024.01.003_bb0320","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1067\/mai.2003.1333","article-title":"IL-13 receptors and signaling pathways: an evolving web","volume":"111","author":"Hershey","year":"2003","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.trecan.2024.01.003_bb0325","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1186\/s12967-018-1746-6","article-title":"Identification of a novel role of IL-13R\u03b12 in human glioblastoma multiforme: interleukin-13 mediates signal transduction through AP-1 pathway","volume":"16","author":"Bhardwaj","year":"2018","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.trecan.2024.01.003_bb0330","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/ijc.26366","article-title":"IL-13 regulates cancer invasion and metastasis through IL-13R\u03b12 via ERK\/AP-1 pathway in mouse model of human ovarian cancer","volume":"131","author":"Fujisawa","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.trecan.2024.01.003_bb0335","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1038\/s41467-017-01392-9","article-title":"Interleukin-13 receptor alpha 2 cooperates with EGFRvIII signaling to promote glioblastoma multiforme","volume":"8","author":"Newman","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2024.01.003_bb0340","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.878365","article-title":"Recent advances in IL-13R\u03b12-directed cancer immunotherapy","volume":"13","author":"Knudson","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trecan.2024.01.003_bb0345","doi-asserted-by":"crossref","first-page":"14701","DOI":"10.1007\/s13277-016-5346-x","article-title":"IL-13 receptor \u03b12 stimulates human glioma cell growth and metastasis through the Src\/PI3K\/Akt\/mTOR signaling pathway","volume":"37","author":"Tu","year":"2016","journal-title":"Tumor Biol."},{"key":"10.1016\/j.trecan.2024.01.003_bb0350","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1165\/rcmb.2019-0446OC","article-title":"N-glycosylation regulates chitinase 3-like-1 and IL-13 ligand binding to IL-13 Receptor \u03b12","volume":"63","author":"He","year":"2020","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.trecan.2024.01.003_bb0355","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.celrep.2013.07.032","article-title":"Chitinase 3-like 1 regulates cellular and tissue responses via IL-13 receptor \u03b12","volume":"4","author":"He","year":"2013","journal-title":"Cell Rep."},{"key":"10.1016\/j.trecan.2024.01.003_bb0360","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1158\/1078-0432.CCR-15-0428","article-title":"Bioactivity and safety of IL13R\u03b12-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma","volume":"21","author":"Brown","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2024.01.003_bb0365","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2024.01.003_bb0370","article-title":"CAR T cell therapy drives endogenous locoregional T cell dynamics in a responding patient with glioblastoma","author":"Jonsson","year":"2021","journal-title":"BioRxiv"},{"key":"10.1016\/j.trecan.2024.01.003_bb0375","doi-asserted-by":"crossref","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","article-title":"Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development","volume":"14","author":"Sahin","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2024.01.003_bb0380","doi-asserted-by":"crossref","first-page":"7380","DOI":"10.1128\/MCB.21.21.7380-7390.2001","article-title":"Claudin-18, a novel downstream target gene for the T\/EBP\/NKX2.1 homeodomain transcription factor, encodes lung- and stomach-specific isoforms through alternative splicing","volume":"21","author":"Niimi","year":"2001","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.trecan.2024.01.003_bb0385","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12890-021-01408-7","article-title":"SPAK\u2013p38 MAPK signal pathway modulates claudin-18 and barrier function of alveolar epithelium after hyperoxic exposure","volume":"21","author":"Shen","year":"2021","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.trecan.2024.01.003_bb0390","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.canlet.2017.05.033","article-title":"Claudin-18 coupled with EGFR\/ERK signaling contributes to the malignant potentials of bile duct cancer","volume":"403","author":"Takasawa","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.trecan.2024.01.003_bb0395","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40364-022-00385-1","article-title":"Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy","volume":"10","author":"Cao","year":"2022","journal-title":"Biomark. Res."},{"key":"10.1016\/j.trecan.2024.01.003_bb0400","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1053\/j.gastro.2018.08.041","article-title":"Loss of tight junction protein claudin 18 promotes progressive neoplasia development in mouse stomach","volume":"155","author":"Hagen","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.trecan.2024.01.003_bb0405","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.trecan.2024.01.003_bb0410","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results","volume":"28","author":"Qi","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2024.01.003_bb0415","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1158\/0008-5472.CAN-14-0337","article-title":"Discovery of mesothelin and exploiting it as a target for immunotherapy","volume":"74","author":"Pastan","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2024.01.003_bb0420","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1097\/00000478-200311000-00003","article-title":"Application of mesothelin immunostaining in tumor diagnosis","volume":"27","author":"Ord\u00f3\u00f1ez","year":"2003","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.trecan.2024.01.003_bb0425","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1476-4598-5-50","article-title":"Mesothelin\u2013MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors","volume":"5","author":"Gubbels","year":"2006","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.trecan.2024.01.003_bb0430","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/nrc745","article-title":"New functions for the matrix metalloproteinases in cancer progression","volume":"2","author":"Egeblad","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.trecan.2024.01.003_bb0435","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1042\/BJ20110282","article-title":"Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK\/ERK and JNK pathways","volume":"442","author":"Chang","year":"2012","journal-title":"Biochem. J."},{"key":"10.1016\/j.trecan.2024.01.003_bb0440","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12943-017-0633-8","article-title":"Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells","volume":"16","author":"He","year":"2017","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.trecan.2024.01.003_bb0445","article-title":"Inhibition of mesothelin as a novel strategy for targeting cancer cells","volume":"7","author":"Wang","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.trecan.2024.01.003_bb0450","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/1476-4598-10-106","article-title":"Mesothelin confers pancreatic cancer cell resistance to TNF-\u03b1-induced apoptosis through Akt\/PI3K\/NF-\u03baB activation and IL-6\/Mcl-1 overexpression","volume":"10","author":"Bharadwaj","year":"2011","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.trecan.2024.01.003_bb0455","doi-asserted-by":"crossref","first-page":"276","DOI":"10.2174\/1871520611313020014","article-title":"The role of mesothelin in tumor progression and targeted therapy","volume":"13","author":"Tang","year":"2013","journal-title":"Anti Cancer Agents Med. Chem."},{"key":"10.1016\/j.trecan.2024.01.003_bb0460","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3390\/cancers14061550","article-title":"Mesothelin: an immunotherapeutic target beyond solid tumors","volume":"14","author":"Faust","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.trecan.2024.01.003_bb0465","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/carcin\/bgr075","article-title":"Mesothelin overexpression promotes autocrine IL-6\/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation","volume":"32","author":"Bharadwaj","year":"2011","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.trecan.2024.01.003_bb0470","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1128\/MCB.20.8.2902-2906.2000","article-title":"Mesothelin is not required for normal mouse development or reproduction","volume":"20","author":"Bera","year":"2000","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.trecan.2024.01.003_bb0475","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.ymthe.2019.07.015","article-title":"Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers","volume":"27","author":"Haas","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.trecan.2024.01.003_bb0480","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab regional CAR T-cell therapy for mesothelioma","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2024.01.003_bb0485","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.2967\/jnumed.117.203877","article-title":"A perspective on the evolving story of PSMA biology, PSMA-based imaging, and endoradiotherapeutic strategies","volume":"59","author":"O'Keefe","year":"2018","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.trecan.2024.01.003_bb0490","first-page":"81","article-title":"Prostate-specific membrane antigen expression in normal and malignant human tissues","volume":"3","author":"Silver","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2024.01.003_bb0495","first-page":"18","article-title":"Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues","volume":"1","author":"Wright","year":"1995","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"10.1016\/j.trecan.2024.01.003_bb0500","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrurol.2016.26","article-title":"Current use of PSMA-PET in prostate cancer management","volume":"13","author":"Maurer","year":"2016","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.trecan.2024.01.003_bb0505","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aag3326","article-title":"PSMA redirects cell survival signaling from the MAPK to the PI3K\u2013AKT pathways to promote the progression of prostate cancer","volume":"10","author":"Caromile","year":"2017","journal-title":"Sci. Signal."},{"key":"10.1016\/j.trecan.2024.01.003_bb0510","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting TGF\u03b2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2024.01.003_bb0515","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/pros.23214","article-title":"Phase I trial of anti-PSMA designer CAR-T cells in prostate cancer: possible role for interacting interleukin 2-T cell pharmacodynamics as a determinant of clinical response","volume":"76","author":"Junghans","year":"2016","journal-title":"Prostate"},{"key":"10.1016\/j.trecan.2024.01.003_bb0520","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1200\/JCO.2022.40.6_suppl.094","article-title":"Safety and early efficacy results from a phase 1, multicenter trial of PSMA-targeted armored CAR T cells in patients with advanced mCRPC","volume":"40","author":"McKean","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2024.01.003_bb0525","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/neuonc\/noaa278","article-title":"Cell-surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery","volume":"23","author":"Haydar","year":"2020","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.trecan.2024.01.003_bb0530","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-15-2428","article-title":"Molecular pathways: targeting B7-H3 (CD276) for Human cancer immunotherapy","volume":"22","author":"Picarda","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2024.01.003_bb0535","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41590-019-0512-0","article-title":"Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups","volume":"20","author":"Andrews","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.trecan.2024.01.003_bb0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108153","article-title":"The role of B7-H3 in tumors and its potential in clinical application","volume":"101","author":"Feng","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.trecan.2024.01.003_bb0545","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.trecan.2018.03.010","article-title":"B7-H3 in cancer \u2013 beyond immune regulation","volume":"4","author":"Flem-Karlsen","year":"2018","journal-title":"Trends Cancer"},{"key":"10.1016\/j.trecan.2024.01.003_bb0550","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1002\/ijc.26238","article-title":"B7-H3 contributes to the metastatic capacity of melanoma cells by modulation of known metastasis-associated genes","volume":"130","author":"Tekle","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.trecan.2024.01.003_bb0555","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.3892\/or.2017.5858","article-title":"B7-H3 is related to tumor progression in ovarian cancer","volume":"38","author":"Zhang","year":"2017","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.trecan.2024.01.003_bb0560","first-page":"66","article-title":"B7-H3 role in the immune landscape of cancer","volume":"6","author":"Castellanos","year":"2017","journal-title":"Am. J. Clin. Exp. Immunol."},{"key":"10.1016\/j.trecan.2024.01.003_bb0565","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1186\/s12935-021-02216-z","article-title":"Correction to: B7-H3 promotes aggression and invasion of hepatocellular carcinoma by targeting epithelial-to-mesenchymal transition via JAK2\/STAT3\/Slug signaling pathway","volume":"21","author":"Kang","year":"2021","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.trecan.2024.01.003_bb0570","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s41591-020-0821-8","article-title":"Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid\/rhabdoid tumors","volume":"26","author":"Theruvath","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2024.01.003_bb0575","doi-asserted-by":"crossref","first-page":"6275","DOI":"10.1158\/0008-5472.CAN-08-4517","article-title":"MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors","volume":"69","author":"Xu","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2024.01.003_bb0580","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/1078-0432.CCR-20-2584","article-title":"B7-H3: an attractive target for antibody-based immunotherapy","volume":"27","author":"Kontos","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2024.01.003_bb0585","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1158\/2159-8290.CD-22-0750","article-title":"Intraventricular B7-H3 CAR T cells for diffuse intrinsic pontine glioma: preliminary first-in-human bioactivity and safety","volume":"13","author":"Vitanza","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2024.01.003_bb0590","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.cell.2018.02.060","article-title":"Comprehensive characterization of cancer driver genes and mutations","volume":"173","author":"Bailey","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2024.01.003_bb0595","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2024.01.003_bb0600","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/s41388-017-0045-7","article-title":"Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies","volume":"37","author":"An","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.trecan.2024.01.003_bb0605","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1093\/neuonc\/now113","article-title":"EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation","volume":"18","author":"Eskilsson","year":"2016","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.trecan.2024.01.003_bb0610","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nrc3918","article-title":"Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma","volume":"15","author":"Furnari","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.trecan.2024.01.003_bb0615","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O'Rourke","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.trecan.2024.01.003_bb0620","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/CJI.0000000000000260","article-title":"Pilot trial of adoptive transfer of chimeric antigen receptor-transduced T cells targeting EGFRvIII in patients with glioblastoma","volume":"42","author":"Goff","year":"2019","journal-title":"J. Immunother."},{"key":"10.1016\/j.trecan.2024.01.003_bb0625","first-page":"5355","article-title":"Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR","volume":"61","author":"Luwor","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2024.01.003_bb0630","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1111\/j.1582-4934.2009.00783.x","article-title":"Targeting a unique EGFR epitope with monoclonal antibody 806 activates NF-\u03baB and initiates tumour vascular normalization","volume":"13","author":"Gan","year":"2009","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.trecan.2024.01.003_bb0635","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1200\/JCO.2022.40.16_suppl.2541","article-title":"STRIvE-01: phase I study of EGFR806 CAR T-cell immunotherapy for recurrent\/refractory solid tumors in children and young adults","volume":"40","author":"Albert","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2024.01.003_bb0640","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nm0198-043","article-title":"Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2","volume":"4","author":"Agrawal","year":"1998","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2024.01.003_bb0645","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.bulcan.2022.08.001","article-title":"MUC1: an emerging target in cancer treatment and diagnosis","volume":"109","author":"Qing","year":"2022","journal-title":"Bull. Cancer"},{"key":"10.1016\/j.trecan.2024.01.003_bb0650","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0036753","article-title":"EGFR-mediated carcinoma cell metastasis mediated by integrin \u03b1v\u03b25 depends on activation of c-Src and cleavage of MUC1","volume":"7","author":"Lau","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.trecan.2024.01.003_bb0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106606","article-title":"MUC1 promotes glioblastoma progression and TMZ resistance by stabilizing EGFRvIII","volume":"187","author":"Tong","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.trecan.2024.01.003_bb0660","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.yexcr.2009.02.011","article-title":"ERK and PI3K regulate different aspects of the epithelial to mesenchymal transition of mammary tumor cells induced by truncated MUC1","volume":"315","author":"Horn","year":"2009","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.trecan.2024.01.003_bb0665","first-page":"10365","article-title":"Muc-1 promotes migration and invasion of oral squamous cell carcinoma cells via PI3K-Akt signaling","volume":"8","author":"Li","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.trecan.2024.01.003_bb0670","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/carcin\/bgw005","article-title":"Mucins and Wnt\/\u03b2-catenin signaling in gastrointestinal cancers: an unholy nexus","volume":"37","author":"Pai","year":"2016","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.trecan.2024.01.003_bb0675","article-title":"The cytoplasmic domain of MUC1 induces hyperplasia in the mammary gland and correlates with nuclear accumulation of \u03b2-catenin","volume":"6","author":"Li","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.trecan.2024.01.003_bb0680","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.e14513","article-title":"Phase I experience with first in class TnMUC1 targeted chimeric antigen receptor T-cells in patients with advanced TnMUC1 positive solid tumors","volume":"39","author":"Gutierrez","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2024.01.003_bb2005","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1158\/1078-0432.CCR-10-0192","article-title":"Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen","volume":"16","author":"Chekmasova","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2024.01.003_bb0685","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41586-021-04061-6","article-title":"Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs","volume":"599","author":"Yarmarkovich","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2024.01.003_bb0690","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1158\/0008-5472.CAN-15-0159","article-title":"Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice","volume":"75","author":"Liu","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2024.01.003_bb0695","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1158\/0008-5472.CAN-15-0139","article-title":"Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity","volume":"75","author":"Caruso","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2024.01.003_bb0700","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1016\/j.ymthe.2017.06.008","article-title":"Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase","volume":"25","author":"Walker","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.trecan.2024.01.003_bb0705","doi-asserted-by":"crossref","first-page":"911","DOI":"10.4049\/jimmunol.1402346","article-title":"Target antigen density governs the efficacy of anti-CD20-CD28-CD3 \u03b6 chimeric antigen receptor-modified effector CD8+ T cells","volume":"194","author":"Watanabe","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.trecan.2024.01.003_bb0710","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1126\/science.abc1855","article-title":"T cell circuits that sense antigen density with an ultrasensitive threshold","volume":"371","author":"Hernandez-Lopez","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.trecan.2024.01.003_bb0715","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/j.cell.2022.03.041","article-title":"Enhanced safety and efficacy of protease-regulated CAR-T cell receptors","volume":"185","author":"Labanieh","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2024.01.003_bb0720","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb6295","article-title":"Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide","volume":"13","author":"Jan","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.trecan.2024.01.003_bb0725","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.ccell.2022.08.008","article-title":"High-performance multiplex drug-gated CAR circuits","volume":"40","author":"Li","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2024.01.003_bb0730","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","article-title":"Clinical lessons learned from the first leg of the CAR T cell journey","volume":"25","author":"Majzner","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2024.01.003_bb0735","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nbt.2459","article-title":"Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells","volume":"31","author":"Kloss","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.trecan.2024.01.003_bb0740","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.cell.2016.01.012","article-title":"Engineering customized cell sensing and response behaviors using synthetic Notch receptors","volume":"164","author":"Morsut","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2024.01.003_bb0745","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","article-title":"Engineering T cells with customized therapeutic response programs using synthetic Notch receptors","volume":"167","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2024.01.003_bb0750","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe7378","article-title":"SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma","volume":"13","author":"Choe","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.trecan.2024.01.003_bb0755","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd8836","article-title":"SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models","volume":"13","author":"Hyrenius-Wittsten","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.trecan.2024.01.003_bb0760","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.cell.2022.03.023","article-title":"Modular design of synthetic receptors for programmed gene regulation in cell therapies","volume":"185","author":"Zhu","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2024.01.003_bb0765","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41586-023-05778-2","article-title":"Co-opting signalling molecules enables logic-gated control of CAR T cells","volume":"615","author":"Tousley","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2024.01.003_bb0770","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.3324\/haematol.2017.183459","article-title":"Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma","volume":"103","author":"Shalabi","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.trecan.2024.01.003_bb0775","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial","volume":"38","author":"Shah","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2024.01.003_bb0780","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","article-title":"Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape-driven relapse in multiple myeloma","volume":"1","author":"Fern\u00e1ndez de Larrea","year":"2020","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.trecan.2024.01.003_bb0785","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2013.32","article-title":"TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy","volume":"2","author":"Grada","year":"2013","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.trecan.2024.01.003_bb0790","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1172\/JCI87366","article-title":"Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies","volume":"126","author":"Ruella","year":"2016","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.trecan.2024.01.003_bb0795","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","article-title":"T cells expressing CD19\/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells","volume":"4","author":"Zah","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.trecan.2024.01.003_bb0800","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1089\/hum.2017.126","article-title":"CD20-CD19 bispecific CAR T cells for the treatment of B-cell malignancies","volume":"28","author":"Martyniszyn","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.trecan.2024.01.003_bb0805","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1172\/JCI83416","article-title":"Tandem CAR T cells targeting HER2 and IL13R\u03b12 mitigate tumor antigen escape","volume":"126","author":"Hegde","year":"2016","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.trecan.2024.01.003_bb0810","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.trecan.2024.01.003_bb0815","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1158\/2643-3230.BCD-20-0208","article-title":"NOT-gated CD93 CAR T cells effectively target AML with minimized endothelial cross-reactivity CD93 CAR T cells for treatment of AML","volume":"2","author":"Richards","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.trecan.2024.01.003_bb0820","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.molimm.2020.09.012","article-title":"Engineered T cells directed at tumors with defined allelic loss","volume":"128","author":"Hamburger","year":"2020","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.trecan.2024.01.003_bb0825","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","article-title":"Allele-specific HLA loss and immune escape in lung cancer evolution","volume":"171","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2024.01.003_bb0830","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2312374120","article-title":"Dual-inhibitory domain iCARs improve the efficiency of the AND-NOT gate CAR T strategy","volume":"120","author":"Bangayan","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.trecan.2024.01.003_bb0835","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","article-title":"Universal chimeric antigen receptors for multiplexed and logical control of T cell responses","volume":"173","author":"Cho","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2024.01.003_bb0840","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41467-021-21078-7","article-title":"Engineering advanced logic and distributed computing in human CAR immune cells","volume":"12","author":"Cho","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2024.01.003_bb0845","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1126\/science.aba6527","article-title":"Designed protein logic to target cells with precise combinations of surface antigens","volume":"369","author":"Lajoie","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.trecan.2024.01.003_bb0850","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1126\/science.abc6270","article-title":"Precise T cell recognition programs designed by transcriptionally linking multiple receptors","volume":"370","author":"Williams","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.trecan.2024.01.003_bb0855","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cels.2020.08.002","article-title":"Discriminatory power of combinatorial antigen recognition in cancer T cell therapies","volume":"11","author":"Dannenfelser","year":"2020","journal-title":"Cell Syst."},{"key":"10.1016\/j.trecan.2024.01.003_bb0860","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/s41587-023-01686-y","article-title":"Single-cell mapping of combinatorial target antigens for CAR switches using logic gates","volume":"41","author":"Kwon","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.trecan.2024.01.003_bb0865","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003826","article-title":"Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells","volume":"10","author":"Tokatlian","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2024.01.003_bb0870","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abm0306","article-title":"A carcinoembryonic antigen-specific cell therapy selectively targets tumor cells with HLA loss of heterozygosity in vitro and in vivo","volume":"14","author":"Sandberg","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.trecan.2024.01.003_bb0875","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.3390\/cancers12082175","article-title":"Targeted cellular micropharmacies: cells engineered for localized drug delivery","volume":"12","author":"Gardner","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.trecan.2024.01.003_bb0880","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","article-title":"CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity","volume":"37","author":"Choi","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.trecan.2024.01.003_bb0885","doi-asserted-by":"crossref","first-page":"7624","DOI":"10.1073\/pnas.1817147116","article-title":"Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice","volume":"116","author":"Xie","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.trecan.2024.01.003_bb0890","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1158\/2326-6066.CIR-20-0280","article-title":"Antitumor effects of CAR T cells redirected to the EDB splice variant of fibronectin","volume":"9","author":"Wagner","year":"2021","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.trecan.2024.01.003_bb0895","article-title":"Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors","volume":"2","author":"Kosti","year":"2021","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.trecan.2024.01.003_bb0900","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2021.100723","article-title":"Generation of hypoxia-sensing chimeric antigen receptor T cells","volume":"2","author":"Kosti","year":"2021","journal-title":"STAR Protoc."},{"key":"10.1016\/j.trecan.2024.01.003_bb0905","doi-asserted-by":"crossref","DOI":"10.1038\/srep39833","article-title":"An oxygen sensitive self-decision making engineered CAR T-cell","volume":"7","author":"Juillerat","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.trecan.2024.01.003_bb0910","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.tips.2012.01.005","article-title":"Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy","volume":"33","author":"Semenza","year":"2012","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.trecan.2024.01.003_bb0915","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ymthe.2016.10.011","article-title":"Masked chimeric antigen receptor for tumor-specific activation","volume":"25","author":"Han","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.trecan.2024.01.003_bb0920","doi-asserted-by":"crossref","first-page":"11694","DOI":"10.18632\/oncotarget.3429","article-title":"High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis","volume":"6","author":"Thomas","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.trecan.2024.01.003_bb0925","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/srep01870","article-title":"Mesothelin binding to CA125\/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation","volume":"3","author":"Chen","year":"2013","journal-title":"Sci. Rep."},{"key":"10.1016\/j.trecan.2024.01.003_bb0930","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1158\/1078-0432.CCR-11-2614","article-title":"Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients","volume":"18","author":"Servais","year":"2012","journal-title":"Clin. Cancer Res."}],"container-title":["Trends in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803324000037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803324000037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T16:39:10Z","timestamp":1729096750000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405803324000037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":187,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S2405803324000037"],"URL":"https:\/\/doi.org\/10.1016\/j.trecan.2024.01.003","relation":{},"ISSN":["2405-8033"],"issn-type":[{"value":"2405-8033","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology","name":"articletitle","label":"Article Title"},{"value":"Trends in Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trecan.2024.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}